Literature DB >> 10655359

Serology of culture-confirmed cases of human granulocytic ehrlichiosis.

M E Aguero-Rosenfeld1, F Kalantarpour, M Baluch, H W Horowitz, D F McKenna, J T Raffalli, T c Hsieh, J Wu, J S Dumler, G P Wormser.   

Abstract

We evaluated the antibody responses in the sera of 24 patients with culture-confirmed human granulocytic ehrlichiosis (HGE). Antibody titers were measured by an indirect immunofluorescent-antibody assay (IFA) by using a local human isolate as the source of antigen. All patients received appropriate antimicrobial treatment. One hundred five serum specimens collected at baseline and at periodic intervals for up to 14 months were included in the study. Seroconversion was observed in 21 of 23 patients (91.3%) from whom convalescent-phase sera were obtained. Antibodies were first detected at an average of 11.5 days after onset of symptoms. Peak titers (>/=2,560 for 71.4% of patients and >/=640 for 95.2% of patients) were obtained an average of 14.7 days after onset of symptoms. Eleven of 13 patients (84.6%) from whom sera were collected between 6 and 10 months after onset of symptoms were still seropositive, and sera from 5 of 10 (50%) patients tested positive between 11 and 14 months after onset of symptoms. For a subset of 71 serum specimens from 17 patients with culture-confirmed HGE also tested by IFA by using either a human isolate from Wisconsin or an Ehrlichia equi isolate from a horse, there was qualitative agreement for 62 serum specimens (87. 3%). Peak titers were higher, however, with the local human HGE isolate, but the difference was not statistically significant. In summary, most patients with culture-confirmed HGE develop antibodies within 2 weeks of onset of symptoms. Antibodies reach high titers during the first month and remain detectable in about one-half of patients at 1 year after onset of symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655359      PMCID: PMC86164     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Reinfection with the agent of human granulocytic ehrlichiosis.

Authors:  H W Horowitz; M Aguero-Rosenfeld; J S Dumler; D F McKenna; T C Hsieh; J Wu; I Schwartz; G P Wormser
Journal:  Ann Intern Med       Date:  1998-09-15       Impact factor: 25.391

2.  Perinatal transmission of the agent of human granulocytic ehrlichiosis.

Authors:  H W Horowitz; E Kilchevsky; S Haber; M Aguero-Rosenfeld; R Kranwinkel; E K James; S J Wong; F Chu; D Liveris; I Schwartz
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

3.  Human granulocytic ehrlichiosis in Massachusetts.

Authors:  S R Telford; T J Lepore; P Snow; C K Warner; J E Dawson
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

4.  Inter- and intralaboratory comparison of Ehrlichia equi and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test.

Authors:  J J Walls; M Aguero-Rosenfeld; J S Bakken; J L Goodman; D Hossain; R C Johnson; J S Dumler
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

5.  Human exposure to a granulocytic Ehrlichia and other tick-borne agents in Connecticut.

Authors:  L A Magnarelli; J W Ijdo; J F Anderson; S J Padula; R A Flavell; E Fikrig
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Antigenic diversity of granulocytic Ehrlichia isolates from humans in Wisconsin and New York and a horse in California.

Authors:  K M Asanovich; J S Bakken; J E Madigan; M Aguero-Rosenfeld; G P Wormser; J S Dumler
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

7.  Clinical and laboratory spectrum of culture-proven human granulocytic ehrlichiosis: comparison with culture-negative cases.

Authors:  H W Horowitz; M E Aguero-Rosenfeld; D F McKenna; D Holmgren; T C Hsieh; S A Varde; S J Dumler; J M Wu; I Schwartz; Y Rikihisa; G P Wormser
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

8.  Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates.

Authors:  M D Ravyn; J L Goodman; C B Kodner; D K Westad; L A Coleman; S M Engstrom; C M Nelson; R C Johnson
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

9.  Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging?

Authors:  J S Bakken; J S Dumler; S M Chen; M R Eckman; L L Van Etta; D H Walker
Journal:  JAMA       Date:  1994-07-20       Impact factor: 56.272

10.  Reactivity of human sera to different strains of granulocytic ehrlichiae in immunodiagnostic assays.

Authors:  L A Magnarelli; J W IJdo; J S Dumler; R Heimer; E Fikrig
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  21 in total

1.  Equine and canine Anaplasma phagocytophilum strains isolated on the island of Sardinia (Italy) are phylogenetically related to pathogenic strains from the United States.

Authors:  Alberto Alberti; Rosanna Zobba; Bernardo Chessa; Maria Filippa Addis; Olivier Sparagano; Maria Luisa Pinna Parpaglia; Tiziana Cubeddu; Gianpaolo Pintori; Marco Pittau
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

2.  Cloning of the major outer membrane protein expression locus in Anaplasma platys and seroreactivity of a species-specific antigen.

Authors:  Tzung-Huei Lai; Nelson G Orellana; Yumi Yuasa; Yasuko Rikihisa
Journal:  J Bacteriol       Date:  2011-04-15       Impact factor: 3.490

3.  Diagnosis of granulocytic ehrlichiosis in humans by immunofluorescence assay.

Authors:  P Brouqui; E Salvo; J S Dumler; D Raoult
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

4.  Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia.

Authors:  S Lotric-Furlan; T Avsic-Zupanc; M Petrovec; W L Nicholson; J W Sumner; J E Childs; F Strle
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

5.  Serodiagnosis of human granulocytic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins.

Authors:  M J Lodes; R Mohamath; L D Reynolds; P McNeill; C P Kolbert; E S Bruinsma; D R Benson; E Hofmeister; S G Reed; R L Houghton; D H Persing
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

6.  Comparison of PCR assays for detection of the agent of human granulocytic ehrlichiosis, Anaplasma phagocytophilum.

Authors:  Robert F Massung; Kimetha G Slater
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

7.  Outcomes of treated human granulocytic ehrlichiosis cases.

Authors:  Alan H Ramsey; Edward A Belongia; Craig M Gale; Jeffrey P Davis
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

8.  Analysis of sequences and loci of p44 homologs expressed by Anaplasma phagocytophila in acutely infected patients.

Authors:  Quan Lin; Ning Zhi; Norio Ohashi; Harold W Horowitz; Maria E Aguero-Rosenfeld; John Raffalli; Gary P Wormser; Yasuko Rikihisa
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

9.  In vivo and in vitro studies on Anaplasma phagocytophilum infection of the myeloid cells of a patient with chronic myelogenous leukaemia and human granulocytic ehrlichiosis.

Authors:  M Bayard-Mc Neeley; A Bansal; I Chowdhury; G Girao; C B Small; K Seiter; J Nelson; D Liveris; I Schwartz; D F Mc Neeley; G P Wormser; M E Aguero-Rosenfeld
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

10.  Reinfection with Anaplasma phagocytophilum in BALB/c mice and cross-protection between two sympatric isolates.

Authors:  Michael L Levin; Dondrae J Coble; Danielle E Ross
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.